+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Vaccine Drugs Development Services Market - Global Forecast 2026-2032- Product Image
mRNA Vaccine Drugs Development Services Market - Global Forecast 2026-2032- Product Image
Sale

mRNA Vaccine Drugs Development Services Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118233
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The mRNA Vaccine Drugs Development Services Market is projected to reach USD 4.28 Billion in 2026. It is expected to continue growing at a CAGR of 11.91%, reaching USD 8.45 Billion by 2032.

Introduction to mRNA Vaccine Drug Development Services

mRNA vaccine drug development services support the progression of messenger RNA vaccine candidates from early research through preclinical evaluation, clinical development, regulatory preparation, manufacturing support, and lifecycle activities. The field combines RNA design, delivery-system development, analytical testing, process development, quality management, and clinical execution. Its importance reflects the need to translate flexible vaccine concepts into reproducible, safe, and regulator-ready products while managing specialized technical and operational requirements.

Transformative Shifts Reshaping mRNA Vaccine Development

The landscape is shifting toward integrated development models that connect sequence design, lipid nanoparticle or other delivery approaches, analytical characterization, formulation, and scalable manufacturing. Developers are also placing greater emphasis on platform standardization, comparability, cold-chain resilience, supply assurance, and quality-by-design principles. Regulatory expectations around novel delivery systems, product characterization, process controls, and clinical evidence are encouraging service providers and sponsors to build more coordinated development pathways rather than treating each stage as an isolated activity.

How Artificial Intelligence Is Changing Development Workflows

Artificial intelligence is increasingly relevant to antigen selection, sequence optimization, formulation screening, process monitoring, trial design, patient stratification, and quality analytics. Machine-learning tools can help identify relationships across large biological and manufacturing datasets, while automation may improve laboratory throughput and consistency. However, meaningful adoption depends on validated data, explainable models, cybersecurity, human oversight, and clear documentation for regulatory review. AI is therefore best viewed as an augmentation layer within controlled development systems, not a substitute for experimental evidence or clinical judgment.

Regional Insights Across the Global Development Ecosystem

North America combines advanced biotechnology capabilities, experienced clinical infrastructure, and mature regulatory pathways, supporting complex mRNA development programs. Europe benefits from strong scientific institutions and coordinated regulatory engagement, although cross-border execution can require careful alignment. Asia-Pacific is strengthening capabilities in RNA research, bioprocessing, clinical operations, and localized manufacturing, with differences in regulatory maturity across markets. Latin America is relevant for clinical recruitment, public-health applications, and regional manufacturing partnerships, while infrastructure and financing conditions vary. The Middle East is pursuing biotechnology capacity and healthcare diversification, creating opportunities for specialized partnerships. Africa presents important unmet-needs and clinical-research opportunities, but sponsors must address infrastructure, supply logistics, workforce development, and regulatory capacity.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets offer a diverse combination of emerging healthcare systems, manufacturing ambitions, and clinical-development opportunities, making regulatory coordination and local partnerships especially important. BRICS economies contribute substantial scientific, manufacturing, and public-health perspectives, but execution requires attention to differing standards, procurement structures, and data environments. The European Union provides a coordinated policy context alongside country-level implementation requirements. G7 members generally offer sophisticated research, regulatory, and biopharmaceutical infrastructure, while NATO countries may bring additional resilience, preparedness, and supply-chain considerations. GCC markets are investing in healthcare modernization and biotechnology capabilities, with partnerships and technology transfer central to development strategies.

Country Insights: Development Priorities Across Key National Markets

The United States and Canada provide strong research, clinical, and regulatory ecosystems. The United Kingdom, Germany, France, Italy, and Spain offer established scientific and healthcare networks, with coordination across national and European requirements remaining important. China, Japan, South Korea, India, and Australia are developing significant RNA research, manufacturing, and clinical capabilities, while local regulatory pathways and technology-transfer expectations should be incorporated early. Brazil and Mexico are important Latin American markets for clinical development, public-health collaboration, and regional access planning. Russia presents a distinct operating environment in which regulatory, sourcing, partnership, and compliance assessments require particular care.

Actionable Priorities for mRNA Development Leaders

Leaders should select partners according to demonstrated capabilities in RNA design, delivery systems, analytical methods, process development, clinical execution, and regulatory documentation rather than relying on a single service category. Development plans should establish comparability strategies early, define critical quality attributes, and connect laboratory data with manufacturing controls. Geographic diversification of suppliers and manufacturing options can strengthen resilience, while region-specific regulatory and clinical plans can reduce execution risk. Organizations should also implement governance for AI-enabled tools, including data-quality controls, validation, auditability, privacy safeguards, and human review. Finally, workforce development and knowledge-transfer mechanisms can improve long-term internal capability.

Research Methodology for the Executive Summary

This executive summary is based on the defined market scope of mRNA vaccine drug development services and a structured assessment of the development value chain, including discovery support, preclinical work, clinical services, analytical testing, manufacturing support, regulatory preparation, and lifecycle activities. Insights are organized across the requested regions, geopolitical or economic groups, and countries. The assessment emphasizes observable industry drivers, operational requirements, technology shifts, regulatory considerations, and development challenges. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific analysis.

Conclusion: Building Resilient, Integrated mRNA Development Pathways

mRNA vaccine drug development services are evolving from specialized technical support into integrated, platform-oriented development ecosystems. Success depends on connecting scientific innovation with robust analytics, scalable processes, regulatory readiness, clinical execution, and resilient supply networks. Regional capabilities are becoming more distributed, while AI and automation can improve decision-making when deployed under rigorous governance. Industry leaders that align partners, data, quality systems, and geographic strategies early will be better positioned to advance mRNA vaccine programs responsibly and efficiently.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. mRNA Vaccine Drugs Development Services Market, by Service Type
7.1. Introduction
7.2. Clinical Development
7.2.1. Phase I Trials
7.2.2. Phase II Trials
7.2.3. Phase III Trials
7.3. Discovery Services
7.3.1. In Vitro Evaluation
7.3.2. Mrna Construct Design
7.3.3. Target Identification
7.4. Manufacturing Services
7.4.1. Commercial Manufacturing
7.4.2. Process Development
7.4.3. Scale Up
7.5. Preclinical Services
7.5.1. Animal Model Studies
7.5.2. Toxicology Studies
7.6. Regulatory Consulting
7.6.1. Dossier Preparation
7.6.2. Submission Support
8. mRNA Vaccine Drugs Development Services Market, by Platform Type
8.1. Introduction
8.2. Circular Mrna
8.3. Nonreplicating Mrna
8.4. Self Ampli?ying Mrna
8.4.1. Nonviral Sarna
8.4.2. Viral Derived Sarna
9. mRNA Vaccine Drugs Development Services Market, by Delivery Technology
9.1. Introduction
9.2. Lipid Nanoparticle
9.2.1. Cationic Lipid
9.2.2. Ionizable Lipid
9.2.3. Neutral Lipid
9.3. Peptide
9.3.1. Cell Penetrating Peptides
9.3.2. Targeting Peptides
9.4. Polymer
9.4.1. Cationic Polymer
9.4.2. Dendrimers
9.4.3. Peg Polymer
10. mRNA Vaccine Drugs Development Services Market, by Therapeutic Area
10.1. Introduction
10.2. Cardiovascular
10.3. Infectious Disease
10.3.1. Bacterial Vaccines
10.3.2. Parasitic Vaccines
10.3.3. Viral Vaccines
10.4. Oncology
10.4.1. Neoantigen Vaccines
10.4.2. Personalized Cancer Vaccines
10.5. Rare Disease
11. mRNA Vaccine Drugs Development Services Market, by End User
11.1. Introduction
11.2. Biotechnology Firms
11.3. Contract Research Organizations
11.3.1. Full Service CROS
11.3.2. Specialized Service CROS
11.4. Pharmaceutical Companies
12. mRNA Vaccine Drugs Development Services Market, by Manufacturing Scale
12.1. Introduction
12.2. Commercial Scale
12.3. Laboratory Scale
12.4. Pilot Scale
13. mRNA Vaccine Drugs Development Services Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. mRNA Vaccine Drugs Development Services Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. mRNA Vaccine Drugs Development Services Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abogen Biosciences Co., Ltd.
17.2. Arcturus Therapeutics Holdings Inc.
17.3. AstraZeneca plc
17.4. BioNTech SE
17.5. Chengdu Walvax Biotechnology Co., Ltd.
17.6. CRISPR Therapeutics AG
17.7. CureVac N.V.
17.8. Daiichi Sankyo Company, Limited
17.9. eTheRNA Immunotherapies NV
17.10. Ethris GmbH
17.11. Genevant Sciences Corporation
17.12. Gennova Biopharmaceuticals Ltd.
17.13. GlaxoSmithKline plc
17.14. Merck & Co., Inc.
17.15. Moderna, Inc.
17.16. Novavax, Inc.
17.17. Pfizer Inc.
17.18. Providence Therapeutics Holdings Inc.
17.19. Regeneron Pharmaceuticals, Inc.
17.20. Sanofi S.A.
17.21. Siam Bioscience Co., Ltd.
17.22. Stemirna Therapeutics Co., Ltd.
17.23. Translate Bio, Inc.
17.24. TriLink BioTechnologies, LLC
17.25. Zydus Cadila
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global mRNA Vaccine Drugs Development Services Market, Years Considered for the Study
FIGURE 2. Global mRNA Vaccine Drugs Development Services Market, Research Design
FIGURE 3. Global mRNA Vaccine Drugs Development Services Market, Research Framework
FIGURE 4. Global mRNA Vaccine Drugs Development Services Market, Data Triangulation
FIGURE 5. Global mRNA Vaccine Drugs Development Services Market Size, 2017-2032 (USD Million)
FIGURE 6. Global mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2025 vs 2032 (%)
FIGURE 7. Global mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2025 vs 2032 (%)
FIGURE 9. Global mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2025 vs 2032 (%)
FIGURE 11. Global mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 13. Global mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global mRNA Vaccine Drugs Development Services Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global mRNA Vaccine Drugs Development Services Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2025 vs 2032 (%)
FIGURE 17. Global mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global mRNA Vaccine Drugs Development Services Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global mRNA Vaccine Drugs Development Services Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global mRNA Vaccine Drugs Development Services Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global mRNA Vaccine Drugs Development Services Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global mRNA Vaccine Drugs Development Services Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global mRNA Vaccine Drugs Development Services Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global mRNA Vaccine Drugs Development Services Market Segmentation & Coverage
TABLE 2. Global mRNA Vaccine Drugs Development Services Market Size, 2017-2032 (USD Million)
TABLE 3. Global mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 4. Global Clinical Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Clinical Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Clinical Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Phase I Trials Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Phase I Trials Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Phase I Trials Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Phase II Trials Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Phase II Trials Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Phase II Trials Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Phase III Trials Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Phase III Trials Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Phase III Trials Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Discovery Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Discovery Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Discovery Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global In Vitro Evaluation Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global In Vitro Evaluation Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global In Vitro Evaluation Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Mrna Construct Design Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Mrna Construct Design Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Mrna Construct Design Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Target Identification Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Target Identification Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Target Identification Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Manufacturing Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Scale Up Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Scale Up Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Scale Up Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Preclinical Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Preclinical Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Preclinical Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Animal Model Studies Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Animal Model Studies Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Animal Model Studies Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Toxicology Studies Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Toxicology Studies Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Toxicology Studies Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Regulatory Consulting Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Regulatory Consulting Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Regulatory Consulting Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Dossier Preparation Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Dossier Preparation Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Dossier Preparation Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Submission Support Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Submission Support Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Submission Support Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 59. Global Circular Mrna Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Circular Mrna Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Circular Mrna Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Nonreplicating Mrna Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Nonreplicating Mrna Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Nonreplicating Mrna Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Self Ampli?ying Mrna Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Self Ampli?ying Mrna Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Self Ampli?ying Mrna Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Nonviral Sarna Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Nonviral Sarna Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Nonviral Sarna Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Viral Derived Sarna Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Viral Derived Sarna Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Viral Derived Sarna Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 75. Global Lipid Nanoparticle Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Lipid Nanoparticle Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Lipid Nanoparticle Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Cationic Lipid Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Cationic Lipid Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Cationic Lipid Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global Ionizable Lipid Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Ionizable Lipid Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Ionizable Lipid Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Neutral Lipid Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Neutral Lipid Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Neutral Lipid Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Peptide Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Peptide Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Peptide Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Cell Penetrating Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Cell Penetrating Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Cell Penetrating Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Targeting Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Targeting Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Targeting Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Polymer Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Polymer Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Polymer Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Cationic Polymer Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Cationic Polymer Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Cationic Polymer Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Dendrimers Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Dendrimers Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Dendrimers Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Peg Polymer Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Peg Polymer Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Peg Polymer Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 109. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Infectious Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Infectious Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Infectious Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Bacterial Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Bacterial Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Bacterial Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Parasitic Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Parasitic Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Parasitic Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global Viral Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Global Viral Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 123. Global Viral Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 124. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 125. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 127. Global Neoantigen Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 128. Global Neoantigen Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. Global Neoantigen Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 130. Global Personalized Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Global Personalized Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 132. Global Personalized Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 133. Global Rare Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Global Rare Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 135. Global Rare Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 136. Global mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. Global Biotechnology Firms Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Biotechnology Firms Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Biotechnology Firms Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Full Service CROS Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Full Service CROS Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Full Service CROS Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Specialized Service CROS Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Global Specialized Service CROS Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. Global Specialized Service CROS Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 151. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 152. Global mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 153. Global Commercial Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 154. Global Commercial Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. Global Commercial Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 156. Global Laboratory Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 157. Global Laboratory Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 158. Global Laboratory Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 159. Global Pilot Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 160. Global Pilot Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. Global Pilot Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 162. Global mRNA Vaccine Drugs Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 165. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 166. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 167. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 168. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 169. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 170. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 171. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Self Ampli?ying Mrna, 2017-2032 (USD Million)
TABLE 172. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 173. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 174. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Peptide, 2017-2032 (USD Million)
TABLE 175. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Polymer, 2017-2032 (USD Million)
TABLE 176. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 177. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 178. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 179. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 181. Asia-Pacific mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 182. North America mRNA Vaccine Drugs Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 183. North America mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 184. North America mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 185. North America mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 186. North America mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 187. North America mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 188. North America mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 189. North America mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 190. North America mRNA Vaccine Drugs Development Services Market Size, by Self Ampli?ying Mrna, 2017-2032 (USD Million)
TABLE 191. North America mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 192. North America mRNA Vaccine Drugs Development Services Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 193. North America mRNA Vaccine Drugs Development Services Market Size, by Peptide, 2017-2032 (USD Million)
TABLE 194. North America mRNA Vaccine Drugs Development Services Market Size, by Polymer, 2017-2032 (USD Million)
TABLE 195. North America mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 196. North America mRNA Vaccine Drugs Development Services Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 197. North America mRNA Vaccine Drugs Development Services Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 198. North America mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. North America mRNA Vaccine Drugs Development Services Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 200. North America mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 201. Latin America mRNA Vaccine Drugs Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 202. Latin America mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 203. Latin America mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 204. Latin America mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 205. Latin America mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 206. Latin America mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 207. Latin America mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 208. Latin America mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 209. Latin America mRNA Vaccine Drugs Development Services Market Size, by Self Ampli?ying Mrna, 2017-2032 (USD Million)
TABLE 210. Latin America mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 211. Latin America mRNA Vaccine Drugs Development Services Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 212. Latin America mRNA Vaccine Drugs Development Services Market Size, by Peptide, 2017-2032 (USD Million)
TABLE 213. Latin America mRNA Vaccine Drugs Development Services Market Size, by Polymer, 2017-2032 (USD Million)
TABLE 214. Latin America mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 215. Latin America mRNA Vaccine Drugs Development Services Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 216. Latin America mRNA Vaccine Drugs Development Services Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 217. Latin America mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 218. Latin America mRNA Vaccine Drugs Development Services Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 219. Latin America mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 220. Europe mRNA Vaccine Drugs Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 221. Europe mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 222. Europe mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 223. Europe mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 224. Europe mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 225. Europe mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 226. Europe mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 227. Europe mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 228. Europe mRNA Vaccine Drugs Development Services Market Size, by Self Ampli?ying Mrna, 2017-2032 (USD Million)
TABLE 229. Europe mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 230. Europe mRNA Vaccine Drugs Development Services Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 231. Europe mRNA Vaccine Drugs Development Services Market Size, by Peptide, 2017-2032 (USD Million)
TABLE 232. Europe mRNA Vaccine Drugs Development Services Market Size, by Polymer, 2017-2032 (USD Million)
TABLE 233. Europe mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 234. Europe mRNA Vaccine Drugs Development Services Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 235. Europe mRNA Vaccine Drugs Development Services Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 236. Europe mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Europe mRNA Vaccine Drugs Development Services Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 238. Europe mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 239. Middle East mRNA Vaccine Drugs Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 240. Middle East mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 241. Middle East mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 242. Middle East mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 243. Middle East mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 244. Middle East mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 245. Middle East mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 246. Middle East mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 247. Middle East mRNA Vaccine Drugs Development Services Market Size, by Self Ampli?ying Mrna, 2017-2032 (USD Million)
TABLE 248. Middle East mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 249. Middle East mRNA Vaccine Drugs Development Services Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 250. Middle East mRNA Vaccine Drugs Development Services Market Size, by Peptide, 2017-2032 (USD Million)
TABLE 251. Middle East mRNA Vaccine Drugs Development Services Market Size, by Polymer, 2017-2032 (USD Million)
TABLE 252. Middle East mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 253. Middle East mRNA Vaccine Drugs Development Services Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 254. Middle East mRNA Vaccine Drugs Development Services Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 255. Middle East mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. Middle East mRNA Vaccine Drugs Development Services Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 257. Middle East mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 258. Africa mRNA Vaccine Drugs Development Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 259. Africa mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 260. Africa mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 261. Africa mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 262. Africa mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 263. Africa mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 264. Africa mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 265. Africa mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 266. Africa mRNA Vaccine Drugs Development Services Market Size, by Self Ampli?ying Mrna, 2017-2032 (USD Million)
TABLE 267. Africa mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 268. Africa mRNA Vaccine Drugs Development Services Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 269. Africa mRNA Vaccine Drugs Development Services Market Size, by Peptide, 2017-2032 (USD Million)
TABLE 270. Africa mRNA Vaccine Drugs Development Services Market Size, by Polymer, 2017-2032 (USD Million)
TABLE 271. Africa mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 272. Africa mRNA Vaccine Drugs Development Services Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 273. Africa mRNA Vaccine Drugs Development Services Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 274. Africa mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 275. Africa mRNA Vaccine Drugs Development Services Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 276. Africa mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 277. Global mRNA Vaccine Drugs Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 278. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 279. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 280. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 281. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 282. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 283. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 284. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 285. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 286. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Self Ampli?ying Mrna, 2017-2032 (USD Million)
TABLE 287. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 288. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 289. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Peptide, 2017-2032 (USD Million)
TABLE 290. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Polymer, 2017-2032 (USD Million)
TABLE 291. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 292. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 293. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 294. ASEAN mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 295. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 296. ASEAN mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 297. GCC mRNA Vaccine Drugs Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 298. GCC mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 299. GCC mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 300. GCC mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 301. GCC mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 302. GCC mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 303. GCC mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 304. GCC mRNA Vaccine Drugs Development Services Market Size, by Platform Type, 2017-2032 (USD Million)
TABLE 305. GCC mRNA Vaccine Drugs Development Services Market Size, by Self Ampli?ying Mrna, 2017-2032 (USD Million)
TABLE 306. GCC mRNA Vaccine Drugs Development Services Market Size, by Delivery Technology, 2017-2032 (USD Million)
TABLE 307. GCC mRNA Vaccine Drugs Development Services Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 308. GCC mRNA Vaccine Drugs Development Services Market Size, by Peptide, 2017-2032 (USD Million)
TABLE 309. GCC mRNA Vaccine Drugs Development Services Market Size, by Polymer, 2017-2032 (USD Million)
TABLE 310. GCC mRNA Vaccine Drugs Development Services Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 311. GCC mRNA Vaccine Drugs Development Services Market Size, by Infectious Disease, 2017-2032 (USD Million)
TABLE 312. GCC mRNA Vaccine Drugs Development Services Market Size, by Oncology, 2017-2032 (USD Million)
TABLE 313. GCC mRNA Vaccine Drugs Development Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 314. GCC mRNA Vaccine Drugs Development Services Market Size, by Contract Research Organizations, 2017-2032 (USD Million)
TABLE 315. GCC mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Scale, 2017-2032 (USD Million)
TABLE 316. European Union mRNA Vaccine Drugs Development Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 317. European Union mRNA Vaccine Drugs Development Services Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 318. European Union mRNA Vaccine Drugs Development Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 319. European Union mRNA Vaccine Drugs Development Services Market Size, by Discovery Services, 2017-2032 (USD Million)
TABLE 320. European Union mRNA Vaccine Drugs Development Services Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 321. European Union mRNA Vaccine Drugs Development Services Market Size, by Preclinical Services, 2017-2032 (USD Million)
TABLE 322. European Union mRNA Vaccine Drugs Development Services Market Size, by Regulatory Consulting, 2017-2032 (USD Million)
TABLE 32

Companies Mentioned

  • Abogen Biosciences Co., Ltd.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Chengdu Walvax Biotechnology Co., Ltd.
  • CRISPR Therapeutics AG
  • CureVac N.V.
  • Daiichi Sankyo Company, Limited
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • Genevant Sciences Corporation
  • Gennova Biopharmaceuticals Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Providence Therapeutics Holdings Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Siam Bioscience Co., Ltd.
  • Stemirna Therapeutics Co., Ltd.
  • Translate Bio, Inc.
  • TriLink BioTechnologies, LLC
  • Zydus Cadila

Related Topics

Related Reports

mRNA Vaccine and Therapeutics Market (4th Edition) by Application Area, Target Disease Indication and Geographical Regions - Trends and Forecast, Till 2035 - Product Image

mRNA Vaccine and Therapeutics Market (4th Edition) by Application Area, Target Disease Indication and Geographical Regions - Trends and Forecast, Till 2035

  • Report
  • 553 Pages
  • Global
From
mRNA Vaccines Market Report 2026-2036 - Product Image

mRNA Vaccines Market Report 2026-2036

  • Report
  • 241 Pages
  • Global
From
mRNA Vaccines Market - Global Forecast 2026-2032 - Product Image

mRNA Vaccines Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
mRNA Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 - Product Image

mRNA Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

  • Report
  • 140 Pages
  • Global
From
mRNA Vaccines and Therapeutics Market Size, Share, Trends and Forecast by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2026-2034 - Product Image

mRNA Vaccines and Therapeutics Market Size, Share, Trends and Forecast by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-User, and Region 2026-2034

  • Report
  • 146 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.